Insmed Inc. (INSM) Shares Climb 15% on Word of Positive Bioequivalence Testing
Shares of Insmed Inc. (Nasdaq: INSM) hiked 15% to a close of 46 cents today, spurred by word the biopharmaceutical company has demonstrated the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF). The company compared G-CSF to FDA-approved Neupogen, used to treat neutropenia, a disorder characterized by an abnormally low number of white blood cells. "These results are very exciting, as they represent Insmed's ability to replicate a protein product, to bring that product rapidly through the clinic and to demonstrate clear bioequivalence to the innovator drug," Dr. Geoffrey Allan, president and CEO of Insmed stated…